Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-1/L1
Pharma
ESMO: AstraZeneca pitches own Padcev combos in bladder cancer
With its Imfinzi-Padcev regimen, AstraZeneca hopes to differentiate from Keytruda-Padcev with less dosing intensity in cisplatin-ineligible MIBC.
Angus Liu
Oct 24, 2026 10:30am
GSK's Jemperli snags FDA nod in rectal cancer after data buzz
Oct 19, 2026 1:24pm
FDA endorses Merck's Keytruda for the 1st time in ovarian cancer
Feb 11, 2026 10:04am
Roche eyes busy 2026 despite Vabysmo miss, Tecentriq flop
Jan 29, 2026 11:23am
Akeso details ivonescimab's 1st overall survival win
Nov 7, 2025 11:30am
Keytruda, Padcev cut risk of death by 50% in MIBC patient subset
Oct 18, 2025 10:30am